DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Here’s What Happened

DiaSorin S.p.A. (OTCMKTS:DSRLF) gapped up before the market opened on Thursday . The stock had previously closed at $74.25, but opened at $81.00. DiaSorin shares last traded at $81.00, with a volume of 100 shares traded.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Zacks Research raised DiaSorin to a “hold” rating in a report on Tuesday, May 12th. UBS Group downgraded DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Piper Sandler assumed coverage on DiaSorin in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft downgraded DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, June 17th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

DiaSorin Trading Up 9.1%

The business has a 50-day moving average of $73.61 and a two-hundred day moving average of $75.87.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.